Irish Continental Group plc (IRCUF)

Blueprint Medicines Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	603.8	572	584.9	334.5	277.1
Revenue Growth (YoY)	5.56%	-2.21%	74.86%	20.71%	-22.47%
Cost of Revenue	25.6	24.9	26.7	22.1	19.5
Gross Profit	578.2	547.1	558.2	312.4	257.6
Other Operating Expenses	443.3	413.2	430.9	261.4	217
Operating Expenses	507.7	477.4	491.4	313.9	256
Operating Income	70.5	69.7	66.8	-1.5	1.6
Interest Expense	-8.5	-6.5	-4.3	-4	-7.8
Interest & Investment Income	0.2	0.1	-	-	-
EBT Excluding Unusual Items	62.2	63.3	62.5	-5.5	-6.2
Gain (Loss) on Sale of Assets	-	-	-	-	-11.2
Asset Writedown	-	-	-	-	-2.3
Other Unusual Items	-	-	-	1.4	1.7
Pretax Income	62.2	63.3	62.5	-4.1	-18
Income Tax Expense	2.3	1.7	2.7	0.8	1
Net Income	59.9	61.6	59.8	-4.9	-19
Net Income to Common	59.9	61.6	59.8	-4.9	-19
Net Income Growth	-2.76%	3.01%	-	-	-
Shares Outstanding (Basic)	165	170	178	187	187
Shares Outstanding (Diluted)	168	173	180	187	187
Shares Change (YoY)	-2.63%	-4.20%	-3.52%	-0.14%	-2.07%
EPS (Basic)	0.36	0.36	0.34	-0.03	-0.10
EPS (Diluted)	0.36	0.36	0.33	-0.03	-0.10
EPS Growth	-0.28%	7.53%	-	-	-
Free Cash Flow	103.1	77.9	50.6	2.6	16
Free Cash Flow Per Share	0.61	0.45	0.28	0.01	0.09
Dividend Per Share	0.155	0.148	0.141	0.090	-
Dividend Growth	5.00%	5.04%	56.56%	-	-
Gross Margin	95.76%	95.65%	95.44%	93.39%	92.96%
Operating Margin	11.68%	12.19%	11.42%	-0.45%	0.58%
Profit Margin	9.92%	10.77%	10.22%	-1.47%	-6.86%
Free Cash Flow Margin	17.08%	13.62%	8.65%	0.78%	5.77%
EBITDA	117.4	114.8	105.3	30.4	30.9
EBITDA Margin	19.44%	20.07%	18.00%	9.09%	11.15%
D&A For EBITDA	46.9	45.1	38.5	31.9	29.3
EBIT	70.5	69.7	66.8	-1.5	1.6
EBIT Margin	11.68%	12.19%	11.42%	-0.45%	0.58%
Effective Tax Rate	3.70%	2.69%	4.32%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.